Surgical implant developer RTI Surgical has started patient enrolment in the FORTE clinical study to evaluate its Fortilink-C, -TS and -L Interbody Fusion (IBF) systems.

The Fortilink-C IBF system is designed to help increase the fusion potential in anterior cervical discectomy and fusion (ACDF) surgery, while Fortilink-TS and Fortilink-L IBF systems are for posterior spine fusion.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

All the three systems feature TETRAfuse 3D Technology, which is an IBF device material meant to aid in optimal outcomes for patients undergoing spinal fusion.

The prospective, multi-centre post-market FORTE study is intended to assess the safety and performance of these devices.

The primary objective of the study is to evaluate radiographic evidence of cervical and lumbar fusion at three-months post-surgery for Fortilink-C IBF System, and six-months post-surgery in case of Fortilink-TS and Fortilink-L IBF systems.

“We believe TETRAfuse represents a new frontier in spine surgery with its design to participate in fusion.”

The study aims to capture and analyse real-world data from adults with degenerative disc disease (DDD) in order to assess pain reduction, as well as the procedural and long-term performance of the devices.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is set to enrol a total of approximately 150 subjects at up to 20 centres in the US over 3.5 years.

RTI Surgical president and CEO Camille Farhat said: “The FORTE study aims to reinforce physician confidence and expand access for patients by showing improved outcomes for appropriate DDD patients based on the unique properties of TETRAfuse 3D Technology.

“We believe TETRAfuse represents a new frontier in spine surgery with its design to participate in fusion, and its bone-like mechanical properties, radiolucency and antibacterial characteristics.”

The company believes that the Fortilink series, which is part of its spine portfolio, has the potential to drive its growth.

Last November, RTI Surgical signed an agreement to further bolster its spinal offering with the acquisition of implant technology company Paradigm Spine.